Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.16
IDXX's Cash-to-Debt is ranked lower than
80% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. IDXX: 0.16 )
Ranked among companies with meaningful Cash-to-Debt only.
IDXX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16  Med: 11.4 Max: No Debt
Current: 0.16
0.16
No Debt
Equity-to-Asset -0.03
IDXX's Equity-to-Asset is ranked lower than
96% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. IDXX: -0.03 )
Ranked among companies with meaningful Equity-to-Asset only.
IDXX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.07  Med: 0.77 Max: 0.9
Current: -0.03
-0.07
0.9
Debt-to-Equity -20.63
IDXX's Debt-to-Equity is ranked lower than
99.99% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. IDXX: -20.63 )
Ranked among companies with meaningful Debt-to-Equity only.
IDXX' s Debt-to-Equity Range Over the Past 10 Years
Min: -133.82  Med: 0.03 Max: 129.54
Current: -20.63
-133.82
129.54
Debt-to-EBITDA 1.95
IDXX's Debt-to-EBITDA is ranked lower than
63% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. IDXX: 1.95 )
Ranked among companies with meaningful Debt-to-EBITDA only.
IDXX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.53  Med: 1.09 Max: 3.15
Current: 1.95
0.53
3.15
Interest Coverage 11.44
IDXX's Interest Coverage is ranked lower than
66% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. IDXX: 11.44 )
Ranked among companies with meaningful Interest Coverage only.
IDXX' s Interest Coverage Range Over the Past 10 Years
Min: 10.54  Med: 43.56 Max: 91.84
Current: 11.44
10.54
91.84
Piotroski F-Score: 9
Altman Z-Score: 11.71
Beneish M-Score: -2.53
WACC vs ROIC
6.19%
39.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 10/10

vs
industry
vs
history
Operating Margin % 21.22
IDXX's Operating Margin % is ranked higher than
90% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. IDXX: 21.22 )
Ranked among companies with meaningful Operating Margin % only.
IDXX' s Operating Margin % Range Over the Past 10 Years
Min: 16.84  Med: 19.31 Max: 21.22
Current: 21.22
16.84
21.22
Net Margin % 13.87
IDXX's Net Margin % is ranked higher than
86% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. IDXX: 13.87 )
Ranked among companies with meaningful Net Margin % only.
IDXX' s Net Margin % Range Over the Past 10 Years
Min: 11.34  Med: 12.66 Max: 13.87
Current: 13.87
11.34
13.87
ROA % 17.59
IDXX's ROA % is ranked higher than
93% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. IDXX: 17.59 )
Ranked among companies with meaningful ROA % only.
IDXX' s ROA % Range Over the Past 10 Years
Min: 13.44  Med: 15.96 Max: 17.59
Current: 17.59
13.44
17.59
ROC (Joel Greenblatt) % 81.51
IDXX's ROC (Joel Greenblatt) % is ranked higher than
90% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. IDXX: 81.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IDXX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 53.83  Med: 63.72 Max: 87.69
Current: 81.51
53.83
87.69
3-Year Revenue Growth Rate 14.50
IDXX's 3-Year Revenue Growth Rate is ranked higher than
73% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. IDXX: 14.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IDXX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 8.4  Med: 14.3 Max: 35.6
Current: 14.5
8.4
35.6
3-Year EBITDA Growth Rate 21.00
IDXX's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. IDXX: 21.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IDXX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -31.5  Med: 15.85 Max: 96.9
Current: 21
-31.5
96.9
3-Year EPS without NRI Growth Rate 18.00
IDXX's 3-Year EPS without NRI Growth Rate is ranked higher than
63% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. IDXX: 18.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IDXX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 15.05 Max: 50.4
Current: 18
0
50.4
GuruFocus has detected 3 Warning Signs with IDEXX Laboratories Inc IDXX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IDXX's 30-Y Financials

Financials (Next Earnings Date: 2018-08-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

IDXX Guru Trades in Q3 2017

Ray Dalio 1,743 sh (New)
Joel Greenblatt 2,209 sh (New)
Steven Cohen 153,100 sh (New)
Lee Ainslie 32,420 sh (+37.49%)
Jim Simons 1,589,800 sh (+17.60%)
Columbia Wanger 120,199 sh (+3.55%)
Mairs and Power 4,598 sh (unchged)
Ron Baron 4,726,336 sh (unchged)
Chuck Royce 300,700 sh (-4.93%)
Ruane Cunniff 2,919 sh (-13.25%)
Caxton Associates 1,700 sh (-34.62%)
» More
Q4 2017

IDXX Guru Trades in Q4 2017

Paul Tudor Jones 4,524 sh (New)
George Soros 2,500 sh (New)
Pioneer Investments 23,972 sh (New)
Joel Greenblatt 4,620 sh (+109.14%)
Jim Simons 1,879,804 sh (+18.24%)
Columbia Wanger 120,199 sh (unchged)
Lee Ainslie Sold Out
Ray Dalio Sold Out
Caxton Associates Sold Out
Ron Baron 4,700,932 sh (-0.54%)
Mairs and Power 4,298 sh (-6.52%)
Ruane Cunniff 2,365 sh (-18.98%)
Chuck Royce 231,604 sh (-22.98%)
Steven Cohen 102,400 sh (-33.12%)
» More
Q1 2018

IDXX Guru Trades in Q1 2018

Ray Dalio 5,495 sh (New)
Spiros Segalas 245,960 sh (New)
Jim Simons 2,088,904 sh (+11.12%)
Pioneer Investments 25,439 sh (+6.12%)
Mairs and Power 4,298 sh (unchged)
George Soros Sold Out
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Ron Baron 4,471,606 sh (-4.88%)
Chuck Royce 183,222 sh (-20.89%)
Ruane Cunniff 1,343 sh (-43.21%)
Paul Tudor Jones 1,407 sh (-68.90%)
» More
2018

IDXX Guru Trades in 2018

Spiros Segalas Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IDXX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2018-03-31 Reduce -4.88%0.17%$157.81 - $204.73 $ 248.1434%4,471,606
Ruane Cunniff 2018-03-31 Reduce -43.21%$157.81 - $204.73 $ 248.1434%1,343
Joel Greenblatt 2018-03-31 Sold Out 0.01%$157.81 - $204.73 $ 248.1434%0
George Soros 2018-03-31 Sold Out 0.01%$157.81 - $204.73 $ 248.1434%0
Ron Baron 2017-12-31 Reduce -0.54%0.02%$147.68 - $168.37 $ 248.1458%4,700,932
Joel Greenblatt 2017-12-31 Add 109.14%0.01%$147.68 - $168.37 $ 248.1458%4,620
George Soros 2017-12-31 New Buy0.01%$147.68 - $168.37 $ 248.1458%2,500
Ruane Cunniff 2017-12-31 Reduce -18.98%$147.68 - $168.37 $ 248.1458%2,365
Ruane Cunniff 2017-09-30 Reduce -13.25%$150.32 - $170.18 $ 248.1457%2,919
Joel Greenblatt 2017-09-30 New Buy0.01%$150.32 - $170.18 $ 248.1457%2,209
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325412    SIC: 2835
Compare:NYSE:LH, XSWX:LONN, TSE:6869, NYSE:IQV, NYSE:DGX, NYSE:A, XTER:SRT3, SZSE:300676, XPAR:BIM, XPAR:ERF, NYSE:PKI, NYSE:BIO, NYSE:QGEN, NAS:DXCM, NAS:ICLR, NAS:EXAS, XTER:AFX, NAS:PRAH, MIL:DIA, NYSE:CRL » details
Traded in other countries:IDXX.Austria, IX1.Germany,
Headquarter Location:USA
IDEXX Laboratories Inc develops, manufactures and distributes products and provide services for companion animal veterinary, livestock and poultry, dairy and water testing markets.

IDEXX Laboratories Inc primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, laboratory equipment for blood-panel analysis, reference lab services, and tests to detect and manage disease in livestock. Idexx gets about 42% of its revenue from outside the United States.

Guru Investment Theses on IDEXX Laboratories Inc

Ron Baron Comments on IDEXX Laboratories - Apr 25, 2017

Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) rose in the first quarter, rallying on strong financial results and multiple expansion. Competitive trends are strong and improving, highlighted by instrument revenue growth, domestic lab growth, rising sales productivity, and stability in rapid assays. We think that IDEXX’s direct go-to-market model coupled with meaningful research and development-driven product enhancements will put steady upward pressure on organic revenue and earnings growth over time. (Neal Rosenberg)

From Ron Baron (Trades, Portfolio)'s first quarter 2017 Baron Partners Fund commentary.

Check out Ron Baron latest stock trades

Ron Baron Comments on IDEXX Laboratories Inc. - Nov 14, 2016

Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) increased in the third quarter. The stock continued to rally on strong financial results and multiple expansion. Competitive trends are strong and improving, highlighted by instrument revenue growth, domestic lab growth, rising sales productivity, and stability in rapid assays. We believe that IDEXX’s direct go-to-market model coupled with research and development-driven product enhancements will put steady upward pressure on organic revenue and earnings growth over time. (Neal Rosenberg)



From Ron Baron (Trades, Portfolio)'s Barons Partners Fund third-quarter 2016 commentary.

Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Oct 21, 2016

Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) increased after the company reported impressive financial results, which led to a meaningful expansion in its trading multiple. We believe the company’s competitive position is strong and improving, as evidenced by its accelerating organic revenue growth, the robust placements of its diagnostic instruments into veterinary clinics, and the higher prices it is capturing across its product portfolio. In addition, IDEXX’s results demonstrated operating margin expansion, which is finally being recognized after several years of intensive investment into its business. Looking forward, we expect to witness sustained double-digit organic revenue growth during the next several years, driven by productivity benefits from its move to a direct sales model in the U.S., the company’s persistent innovation pipeline, and returns on its intensive investment into international markets.





From Baron Funds' Barron Asset Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Oct 11, 2016

Top 10 holding IDEXX Laboratories, Inc. (NASDAQ:IDXX) is the leading provider of diagnostics to the veterinary industry. The company spends six times more on R&D annually than all its competitors combined. As a result, it has continuously improved its menu of diagnostics, which we believe is unsurpassed in the industry. IDEXX is benefiting from secular growth spending on pets, driven by favorable demographics, increased use of diagnostics, and an increasing focus on preventative care. The company’s products are sold via a razor/razorblade model, which produces high retention rates and incremental margins. We think that IDEXX’s direct go-to-market model coupled with meaningful R&D-driven product enhancements will continue to boost revenue and earnings growth over time.



From Baron Funds' fall 2016 newsletter.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Aug 17, 2016

IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading company in veterinary diagnostics, rallied in the second quarter after reporting strong financial results. Organic revenue growth was up 11%, driven by instrument revenue gains of 16% (and new placements up 25%), consumables’ sales up 12%, and reference labs sales up 15%. The company’s efforts to build a direct sales force and introduce new innovative products are showing terrific results. We expect revenue growth to accelerate as additional tests gain traction and the productivity of the new salesforce continues to improve. The company remained aggressive with its share repurchase program. We applaud the company’s plan to take on some leverage to buy in shares, especially as they bought at the lows, and since we believe the business is so stable and annuity-like that the balance sheet should have a reasonable amount of debt to optimize equity returns for the shareholders.





From Baron Funds' Small Cap Fund second quarter 2016 shareholder letter.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Jul 25, 2016

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported another quarter of strong financial results. We continue to believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 25% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories continued to grow at more than twice the rate of its main competitor. We believe that these trends, coupled with the revenue contributions from its new proprietary tests, has potential for better revenue and earnings growth during the next few years.



Baron Asset Fund second quarter shareholder letter.



Check out Ron Baron latest stock trades

Top Ranked Articles about IDEXX Laboratories Inc

5 Companies Hit 52-Week Highs As of late, multiple companies have all managed to achieve yearly highs
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs. Read more...
IDEXX Laboratories to Release 2018 Second Quarter Financial Results
IDEXX Laboratories to Present at William Blair Growth Stock Conference
IDEXX Laboratories to Present at Stifel 2018 Dental and Veterinary Conference
Research Report Identifies Cara Therapeutics, MGE Energy, IDEXX Laboratories, Sterling Construction, TTM Technologies, and Regis with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
IDEXX Laboratories to Release 2018 First Quarter Financial Results
Spiros Segalas Picks Up 5 Stocks in 1st Quarter An oilfield services company is the guru’s largest new position
Spiros Segalas (Trades, Portfolio), portfolio manager of the Harbor Capital Appreciation Fund, released his first-quarter portfolio on Tuesday, disclosing he established five new positions. Read more...
IDEXX Laboratories to Present at Two Conferences
IDEXX Advances Power of SediVue Dx with Latest Software Update
IDEXX Laboratories to Release 2017 Fourth Quarter and Full-Year Financial Results

Ratios

vs
industry
vs
history
PE Ratio 78.03
IDXX's PE Ratio is ranked lower than
83% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. IDXX: 78.03 )
Ranked among companies with meaningful PE Ratio only.
IDXX' s PE Ratio Range Over the Past 10 Years
Min: 15.18  Med: 32.11 Max: 76.36
Current: 78.03
15.18
76.36
Forward PE Ratio 59.88
IDXX's Forward PE Ratio is ranked lower than
98% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IDXX: 59.88 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 78.03
IDXX's PE Ratio without NRI is ranked lower than
83% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. IDXX: 78.03 )
Ranked among companies with meaningful PE Ratio without NRI only.
IDXX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.18  Med: 32.11 Max: 76.36
Current: 78.03
15.18
76.36
Price-to-Owner-Earnings 76.35
IDXX's Price-to-Owner-Earnings is ranked lower than
75% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. IDXX: 76.35 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IDXX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.36  Med: 35.52 Max: 74.71
Current: 76.35
21.36
74.71
PS Ratio 10.83
IDXX's PS Ratio is ranked lower than
72% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. IDXX: 10.83 )
Ranked among companies with meaningful PS Ratio only.
IDXX' s PS Ratio Range Over the Past 10 Years
Min: 1.75  Med: 4.13 Max: 10.6
Current: 10.83
1.75
10.6
Price-to-Free-Cash-Flow 73.90
IDXX's Price-to-Free-Cash-Flow is ranked lower than
76% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. IDXX: 73.90 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
IDXX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.01  Med: 34.78 Max: 84.69
Current: 73.9
13.01
84.69
Price-to-Operating-Cash-Flow 58.83
IDXX's Price-to-Operating-Cash-Flow is ranked lower than
82% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. IDXX: 58.83 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IDXX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.4  Med: 25.18 Max: 57.57
Current: 58.83
11.4
57.57
EV-to-EBIT 51.10
IDXX's EV-to-EBIT is ranked lower than
76% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. IDXX: 51.10 )
Ranked among companies with meaningful EV-to-EBIT only.
IDXX' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.5  Med: 22.05 Max: 51.2
Current: 51.1
10.5
51.2
EV-to-EBITDA 42.92
IDXX's EV-to-EBITDA is ranked lower than
80% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. IDXX: 42.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
IDXX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 18.05 Max: 43
Current: 42.92
8.2
43
EV-to-Revenue 10.96
IDXX's EV-to-Revenue is ranked lower than
69% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. IDXX: 10.96 )
Ranked among companies with meaningful EV-to-Revenue only.
IDXX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.8  Med: 4.2 Max: 11
Current: 10.96
1.8
11
PEG Ratio 5.03
IDXX's PEG Ratio is ranked lower than
63% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. IDXX: 5.03 )
Ranked among companies with meaningful PEG Ratio only.
IDXX' s PEG Ratio Range Over the Past 10 Years
Min: 0.78  Med: 2.28 Max: 4.7
Current: 5.03
0.78
4.7
Shiller PE Ratio 130.26
IDXX's Shiller PE Ratio is ranked lower than
90% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. IDXX: 130.26 )
Ranked among companies with meaningful Shiller PE Ratio only.
IDXX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 26.11  Med: 51.27 Max: 127.8
Current: 130.26
26.11
127.8
Current Ratio 0.96
IDXX's Current Ratio is ranked lower than
90% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. IDXX: 0.96 )
Ranked among companies with meaningful Current Ratio only.
IDXX' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 3 Max: 8.34
Current: 0.96
0.9
8.34
Quick Ratio 0.72
IDXX's Quick Ratio is ranked lower than
89% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. IDXX: 0.72 )
Ranked among companies with meaningful Quick Ratio only.
IDXX' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 2.06 Max: 7.55
Current: 0.72
0.71
7.55
Days Inventory 69.73
IDXX's Days Inventory is ranked higher than
54% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. IDXX: 69.73 )
Ranked among companies with meaningful Days Inventory only.
IDXX' s Days Inventory Range Over the Past 10 Years
Min: 67.49  Med: 81.19 Max: 89.55
Current: 69.73
67.49
89.55
Days Sales Outstanding 46.39
IDXX's Days Sales Outstanding is ranked higher than
75% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. IDXX: 46.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
IDXX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.43  Med: 41.31 Max: 43.49
Current: 46.39
37.43
43.49
Days Payable 28.48
IDXX's Days Payable is ranked lower than
84% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. IDXX: 28.48 )
Ranked among companies with meaningful Days Payable only.
IDXX' s Days Payable Range Over the Past 10 Years
Min: 13.82  Med: 22.5 Max: 28.04
Current: 28.48
13.82
28.04

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.80
IDXX's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. IDXX: 2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IDXX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -21.4  Med: 2.25 Max: 6.2
Current: 2.8
-21.4
6.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 7.44
IDXX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
76% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. IDXX: 7.44 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IDXX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.49  Med: 2.62 Max: 5.74
Current: 7.44
1.49
5.74
Price-to-Intrinsic-Value-DCF (Earnings Based) 4.18
IDXX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
71% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. IDXX: 4.18 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
IDXX' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.06  Med: 2.29 Max: 3.74
Current: 4.18
1.06
3.74
Price-to-Median-PS-Value 2.62
IDXX's Price-to-Median-PS-Value is ranked lower than
88% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. IDXX: 2.62 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IDXX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 0.89 Max: 2.08
Current: 2.62
0.43
2.08
Price-to-Peter-Lynch-Fair-Value 4.76
IDXX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
83% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. IDXX: 4.76 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
IDXX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.82  Med: 2.01 Max: 4.9
Current: 4.76
0.82
4.9
Earnings Yield (Greenblatt) % 1.96
IDXX's Earnings Yield (Greenblatt) % is ranked higher than
66% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. IDXX: 1.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IDXX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2  Med: 4.5 Max: 9.5
Current: 1.96
2
9.5
Forward Rate of Return (Yacktman) % 17.27
IDXX's Forward Rate of Return (Yacktman) % is ranked higher than
77% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. IDXX: 17.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IDXX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 12.9  Med: 16.7 Max: 22.4
Current: 17.27
12.9
22.4

More Statistics

Revenue (TTM) (Mil) $2,044.69
EPS (TTM) $ 3.18
Beta0.59
Volatility23.57%
52-Week Range $146.09 - 243.74
Shares Outstanding (Mil)86.86

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 2,227 2,459 2,719
EBIT (Mil $) 493 570 624
EBITDA (Mil $) 584 666 707
EPS ($) 4.11 4.79 5.36
EPS without NRI ($) 4.11 4.79 5.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
17.58%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 99
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}